185 related articles for article (PubMed ID: 7517719)
21. Bispecific antibody fragments with CD20 X CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma.
Brandl M; Grosse-Hovest L; Holler E; Kolb HJ; Jung G
Exp Hematol; 1999 Aug; 27(8):1264-70. PubMed ID: 10428503
[TBL] [Abstract][Full Text] [Related]
22. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
23. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
Chen X; Shen D; Sun T; Bai J; Huang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
[TBL] [Abstract][Full Text] [Related]
24. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
25. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
[TBL] [Abstract][Full Text] [Related]
27. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
[TBL] [Abstract][Full Text] [Related]
28. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
30. CD3 x CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low-malignancy non-Hodgkin's lymphoma.
Manzke O; Titzer S; Tesch H; Diehl V; Bohlen H
Cancer Immunol Immunother; 1997; 45(3-4):198-202. PubMed ID: 9435873
[TBL] [Abstract][Full Text] [Related]
31. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH
Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731
[TBL] [Abstract][Full Text] [Related]
32. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
33. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
[TBL] [Abstract][Full Text] [Related]
34. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.
Schmidt-Wolf IG; Negrin RS; Kiem HP; Blume KG; Weissman IL
J Exp Med; 1991 Jul; 174(1):139-49. PubMed ID: 1711560
[TBL] [Abstract][Full Text] [Related]
35. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
[TBL] [Abstract][Full Text] [Related]
36. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human malignant B cells.
Pulczynski S
Leuk Lymphoma; 1994 Oct; 15(3-4):243-52. PubMed ID: 7532507
[TBL] [Abstract][Full Text] [Related]
37. CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow.
Manzke O; Berthold F; Huebel K; Tesch H; Diehl V; Bohlen H
Int J Cancer; 1999 Mar; 80(5):715-22. PubMed ID: 10048973
[TBL] [Abstract][Full Text] [Related]
38. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
Honeychurch J; Cruise A; Tutt AL; Glennie MJ
Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
[TBL] [Abstract][Full Text] [Related]
39. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
40. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
